Crnic Institute Human Trisome Project - Tofacitinib for Immune Skin Conditions in Down Syndrome: PolyA RNAseq from whole blood
RNA-seq (gene expression) · human · 194 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 194 samples: 194 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE330188_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1463078 and SRA study SRP698928. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 194 sample titles: 194 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9720753 Subject TOFA_0002, Baseline
- GSM9720754 Subject TOFA_0002, 2 weeks tofacitinib
- GSM9720755 Subject TOFA_0002, 8 weeks tofacitinib
- GSM9720756 Subject TOFA_0002, 16 weeks tofacitinib
- GSM9720757 Subject TOFA_0002, 40 weeks tofacitinib
- GSM9720758 Subject TOFA_02F1, Baseline
- GSM9720759 Subject TOFA_02F1, 2 weeks tofacitinib
- GSM9720760 Subject TOFA_02F1, 8 weeks tofacitinib
- GSM9720761 Subject TOFA_02F1, 16 weeks tofacitinib
- GSM9720762 Subject TOFA_0396, Baseline
- GSM9720763 Subject TOFA_0396, 2 weeks tofacitinib
- GSM9720764 Subject TOFA_0396, 8 weeks tofacitinib
- GSM9720765 Subject TOFA_0396, 16 weeks tofacitinib
- GSM9720766 Subject TOFA_0396, 40 weeks tofacitinib
- GSM9720767 Subject TOFA_0D62, Baseline
- GSM9720768 Subject TOFA_0D62, 2 weeks tofacitinib
- GSM9720769 Subject TOFA_0D62, 8 weeks tofacitinib
- GSM9720770 Subject TOFA_0D62, 16 weeks tofacitinib
- GSM9720771 Subject TOFA_0D6A, Baseline
- GSM9720772 Subject TOFA_0D6A, 2 weeks tofacitinib
- GSM9720773 Subject TOFA_0D6A, 16 weeks tofacitinib
- GSM9720774 Subject TOFA_0D6A, 40 weeks tofacitinib
- GSM9720775 Subject TOFA_17BD, Baseline
- GSM9720776 Subject TOFA_17BD, 2 weeks tofacitinib
- GSM9720777 Subject TOFA_17BD, 8 weeks tofacitinib
- GSM9720778 Subject TOFA_17BD, 16 weeks tofacitinib
- GSM9720779 Subject TOFA_17BD, 40 weeks tofacitinib
- GSM9720780 Subject TOFA_2E7C, Baseline
- GSM9720781 Subject TOFA_2E7C, 2 weeks tofacitinib
- GSM9720782 Subject TOFA_2E7C, 8 weeks tofacitinib
- GSM9720783 Subject TOFA_2E7C, 40 weeks tofacitinib
- GSM9720784 Subject TOFA_34EC, Baseline
- GSM9720785 Subject TOFA_34EC, 2 weeks tofacitinib
- GSM9720786 Subject TOFA_34EC, 8 weeks tofacitinib
- GSM9720787 Subject TOFA_34EC, 16 weeks tofacitinib
- GSM9720788 Subject TOFA_34EC, 40 weeks tofacitinib
- GSM9720789 Subject TOFA_36FD, Baseline
- GSM9720790 Subject TOFA_36FD, 2 weeks tofacitinib
- GSM9720791 Subject TOFA_36FD, 8 weeks tofacitinib
- GSM9720792 Subject TOFA_36FD, 16 weeks tofacitinib
+ 154 more — browse all 194 samples with per-sample file links →
- GSE190125 Crnic Institute Human Trisome Project: PolyA RNA-seq from whole blood 400 samples shares institute, trisome, project, crnic, polya, whole
- GSE296449 Crnic Institute Human Trisome Project - Trisomy 21 Model Atlas: PolyA RNA-seq from human iPSC-derived Hepatocyte-like cells 20 samples shares institute, trisome, project, crnic, polya
- GSE29943 Unstressed HeLa cells and ELAVL1/HuR knock down conditions: polyA RNA-Seq, small RNA-Seq, and PAR-CLIP 9 samples shares conditions, polya
- GSE286345 Sex-specific transcriptional differences in Gulf War Illness patients under stressful conditions 242 samples shares conditions
- GSE190185 Cholesterol and matrisome pathways dysregulated in APOE ε4 human microglia and astrocytes [isogenicAPOE] 94 samples shares trisome
- GSE328878 Transcriptomic comparison of RA vs healthy monocytes undergoing different ex vivo activation conditions 72 samples shares conditions
- GSE246180 Comparative Analysis of the Physiological and Transport Functions of Various Sources of Renal Proximal Tubule Cells Under Static and Fluidic Conditions in PhysioMimix TC12 Platform 69 samples shares conditions
- GSE80688 Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate for Alopecia Areata and Variants 56 samples shares tofacitinib
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.